Best CDMOs in United Kingdom — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
37
CDMOs in region
21
Fully scored
8
With FDA records
25
FDA inspections
69
EMA/MHRA GMP certs
CDMO Signal tracks 37 biopharma CDMOs with confirmed United Kingdom manufacturing facilities, of which 21 are fully scored across the four-pillar composite Signal Score. Across all modalities, Charles River Laboratories, ReciBioPharm, and Pharmaron Biologics lead the United Kingdom ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within United Kingdom — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.
UK-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed British facilities. Post-Brexit UK operates under MHRA as an independent regulator distinct from EMA, though the two frameworks broadly align on GMP standards. UK CDMOs supplying EU markets require both MHRA and EMA GMP certification; those supplying US markets need FDA inspection posture. This ranking includes any CDMO with a UK manufacturing site — a CDMO with UK + EU + US facilities appears on each region ranking. Filtering is derived from each CDMO's declared facility locations.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 2 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 3 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 4 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 6 insp · 10 GMP | Available | 2 programs |
| 5 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 6 |
MedPharm (Tergus Pharma)
Guildford UK, Durham NC
|
80.8 | 100.0 | 1 insp · 0 GMP | Available | 0 programs |
| 7 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.2 | 98.8 | 1 insp · 1 GMP | Available | 0 programs |
| 8 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.7 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 9 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 10 |
OR
Ori Biotech
London, UK
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 11 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 12 |
CK
Codiak BioSciences (Sarepta)
Cambridge, MA
|
78.0 | 100.0 | 1 insp · 0 GMP | — | 16 programs |
| 13 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
77.1 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 14 |
SY
Symbiosis Pharmaceutical Services
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 9 GMP | — | 0 programs |
| 15 |
HH
HiTech Health
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 16 |
Abzena
San Diego, CA; Bristol, PA; Cambridge, UK
|
64.0 | — | — | Available | 0 programs |
| 17 |
Catachem Inc.
Oxford, CT
|
61.5 | — | — | 0 programs | |
| 18 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 19 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 20 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 21 |
EV
Evox Therapeutics
Oxford, UK
|
57.5 | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Centillion Technology Limited
Newcastle upon Tyne, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Codis
St. Louis, MO (UK site: Haverhill, Suffolk, UK)
|
Profiled | — | — | — | 0 programs |
| — |
Sterling Pharma Solutions
Cramlington, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Upperton Pharma Solutions
Nottingham, UK
|
Profiled | — | — | — | 0 programs |
| — |
Spur Therapeutics
London, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Touchlight
Hampton, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Vectura (now Molex/Vectura)
Chippenham, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Croda Pharma (formerly Avanti Polar Lipids)
Snaith, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Biopharma Group
Swindon, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Genzyme (Sanofi)
Cambridge, MA (division of Sanofi, HQ: Paris, France)
|
Profiled | — | — | — | 0 programs |
| — |
Almac Group
Craigavon, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Argenta
London, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Quotient Sciences
Nottingham, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
BioAscent Discovery
Newhouse, Scotland, UK
|
Profiled | — | — | — | 0 programs |
How has post-Brexit MHRA / EMA divergence affected UK CDMO selection?
Since 1 January 2021 the UK has operated MHRA as an independent regulator distinct from EMA. Practically this means: (1) UK manufacturing for EU-market supply requires a separate EMA GMP certificate, held by an EU-based Qualified Person; (2) EU manufacturing for UK-market supply requires MHRA acceptance, though MHRA has continued to recognize EMA GMP inspections under transitional arrangements; (3) the batches themselves may need to be released twice (once by an EU QP for EU supply, once by a UK QP for UK supply). CDMOs with UK + EU footprints are increasingly common in response; UK-only CDMOs need to arrange separate EU QP release for European supply. The Signal Score's Quality Compliance pillar captures both MHRA and EMA GMP certificates, so dual-jurisdiction CDMOs typically rank higher on this pillar.
Which UK CDMOs also cover FDA (US) regulatory geography?
UK CDMOs with US FDA inspection history qualify to supply US-market programs; those without FDA posture are limited to UK + EU. British CDMOs with FDA inspection density typically rank higher on the Signal Score's Quality Compliance pillar because that pillar aggregates FDA + EMA + MHRA data directly. Cross-check with the US region ranking — CDMOs appearing on both UK and US rankings have demonstrated multi-jurisdictional inspection posture, which materially reduces regulatory tech-transfer risk for programs supplying both markets.
How CDMO Signal identifies UK manufacturing presence
UK region attribution derives from each CDMO's declared facility locations. A location string containing UK-specific tokens (England, Scotland, Wales, Northern Ireland, London, Oxford, Cambridge, Liverpool, Manchester, Edinburgh, or 'UK'/'United Kingdom') places the CDMO in the UK region. Multi-site CDMOs appear in every applicable region — a Cambridge + Basel + Boston CDMO shows on UK, Europe, Switzerland, and USA rankings. Sponsors evaluating for a specific program should verify facility-level detail on the individual CDMO profile page — a CDMO with UK presence may only run some processes there and route others through their non-UK sites.
Browse by modality within United Kingdom
Modality-specific rankings for United Kingdom-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed United Kingdom facilities.
AAV / Gene Therapy (15)
CAR-T (4)
Lentiviral Vector (12)
Cell Therapy (8)
mRNA / LNP (4)
Plasmid DNA (8)
Biologics / mAb (6)
Adenoviral Vector (3)
Gene Editing (3)
Exosome / Extracellular Vesicle (2)
Recombinant Proteins (2)
ADC (Antibody-Drug Conjugate) (6)
Gene Therapy (16)
Cell & Gene Therapy (20)
Viral Vector (15)